Constellation Pharmaceuticals, Inc.
METHODS OF TREATING MYELOPROLIFERATIVE DISORDERS

Last updated:

Abstract:

The present disclosure relates to the use of 2-((4S)-6-(4-chlorophenyl)-1-methyl-4H-benzo[c]isoxazolo[4,5-e]azepin-4-y- l)acetamide, and pharmaceutically acceptable salts thereof, for treating myelofibrosis.

Status:
Application
Type:

Utility

Filling date:

7 Oct 2020

Issue date:

4 Feb 2021